neurocrine
biosciences
voyager
therapeutics
present
new
data
demonstrating
treatment
investigational
gene
therapy
showed
sustained
improvement
motor
data
investigational
gene
therapy
treatment
presented
mds
virtual
congress
treatment
showed
sustained
improvement
motor
function
including
greater
time
without
troublesome
dyskinesia
reduction
unified
parkinson
disease
rating
scale
updrs
part
iii
scores
reduction
amount
medications
three
years
patients
parkinson
disease
patients
treated
continued
experience
improvement
disease
staging
three
years
assessed
modified
hoehn
yahr
scale
enrollment
registrational
clinical
trial
planned
later
year
san
diego
cambridge
globe
newswire
neurocrine
biosciences
nasdaq
nbix
voyager
therapeutics
nasdaq
vygr
today
announced
data
phase
ib
efficacy
safety
study
demonstrating
treatment
investigational
gene
therapy
showed
sustained
improvement
motor
function
including
greater
time
without
troublesome
dyskinesia
reduction
unified
parkinson
disease
rating
scale
updrs
part
iii
scores
reduction
amount
medications
patients
parkinson
disease
study
reduced
average
time
hours
improved
average
time
without
troublesome
dyskinesia
hours
patients
advanced
parkinson
disease
three
years
across
three
cohorts
addition
patients
treated
continued
show
improvement
disease
staging
three
years
assessed
modified
hoehn
yahr
scale
new
data
along
data
another
phase
ib
trial
presented
today
mds
virtual
congress
september
congress
data
trial
treatment
showed
sustained
reduction
diary
time
average
hours
baseline
hours
improved
diary
time
without
troublesome
dyskinesia
average
hours
baseline
hours
across
cohorts
reported
patients
advanced
parkinson
disease
also
showed
sustained
improvement
motor
function
three
years
measured
updrs
part
iii
medication
scores
points
baseline
points
across
cohorts
per
clinician
assessment
requirements
parkinson
disease
medications
also
reduced
cohorts
daily
dose
reductions
average
mg
day
respectively
baseline
mg
day
respectively
data
trial
patients
showed
reduced
diary
time
average
hours
increased
diary
good
time
hours
baselines
hours
hours
respectively
study
showed
sustained
improvement
motor
function
two
years
improved
updrs
part
iii
medication
scores
points
baseline
requirements
parkinson
disease
medications
also
reduced
daily
dose
reduction
average
pf
mg
day
baseline
mg
day
preliminary
safety
data
studies
suggest
study
serious
adverse
events
saes
reported
common
adverse
events
reported
headache
hypoesthesia
musculoskeletal
pain
upper
respiratory
tract
infection
headache
nausea
depression
promising
see
three
years
single
administration
investigational
gene
therapy
treatment
showed
sustained
reduction
time
well
improvement
time
without
troublesome
dyskinesia
measures
motor
function
patients
parkinson
disease
said
chad
christine
primary
author
lead
investigator
study
professor
neurology
university
california
san
francisco
ucsf
weill
institute
neurosciences
parkinson
disease
patients
motor
function
would
expected
worsen
three
years
making
results
encouraging
standard
care
advanced
parkinson
disease
significantly
changed
decades
hope
potential
become
first
gene
therapy
parkinson
parkinson
disease
chronic
progressive
debilitating
neurodegenerative
disorder
affects
approximately
one
million
people
six
million
people
worldwide
characterized
loss
dopamine
neuronal
degeneration
concomitant
loss
aromatic
acid
decarboxylase
aadc
enzyme
required
synthesize
dopamine
brain
leading
associated
impairment
motor
neuropsychiatric
autonomic
functions
pleased
results
studies
show
treatment
investigational
may
help
restore
brain
ability
convert
levodopa
dopamine
said
eiry
roberts
chief
medical
officer
neurocrine
biosciences
hope
help
patients
experience
less
time
time
improve
motor
symptom
control
plan
enrollment
registrational
clinical
trial
year
look
forward
evaluating
patients
parkinson
investigational
recombinant
viral
serotype
vector
encoding
gene
human
aadc
designed
help
produce
aadc
enzyme
brain
cells
convert
levodopa
dopamine
encouraged
congruence
data
including
clinical
outcomes
clinical
studies
said
omar
khwaja
chief
medical
officer
head
research
development
voyager
therapeutics
results
promising
show
approach
potential
transform
treatment
parkinson
disease
help
improve
lives
patients
additional
information
available
demand
registered
participants
october
mds
meeting
website
congress
christine
cw
richardson
rm
van
laar
ad
et
al
safety
clinical
outcomes
trial
aadc
gene
therapy
advanced
parkinson
disease
poster
update
genetics
movement
disorders
september
est
prerecorded
presentation
poster
update
genetics
movement
disorders
september
est
prerecorded
presentation
factor
sa
van
laar
ad
richardson
rm
et
al
aadc
gene
therapy
administered
via
posterior
approach
results
trial
advanced
parkinson
disease
poster
poster
tour
launches
september
est
prerecorded
presentation
parkinson
disease
parkinson
disease
chronic
progressive
debilitating
neurodegenerative
disease
affects
approximately
one
million
people
six
million
people
worldwide
characterized
loss
dopamine
neuronal
degeneration
concomitant
loss
aromatic
acid
decarboxylase
aadc
enzyme
required
synthesize
dopamine
brain
leading
associated
impairment
motor
neuropsychiatric
autonomic
functions
dopamine
chemical
messenger
produced
brain
involved
control
movement
made
aadc
converts
chemical
levodopa
dopamine
parkinson
disease
progresses
less
aadc
enzyme
parts
brain
levodopa
converted
dopamine
investigational
recombinant
viral
aav
serotype
vector
encoding
gene
human
aadc
designed
help
produce
aadc
enzyme
brain
cells
convert
levodopa
dopamine
administered
brain
using
intraoperative
monitoring
magnetic
resonance
imaging
mri
targeted
delivery
clinical
trial
paused
temporarily
april
due
pandemic
neurocrine
biosciences
voyager
therapeutics
plan
phase
randomized
controlled
clinical
trial
evaluate
safety
efficacy
patients
diagnosed
parkinson
disease
least
four
years
least
three
hours
time
day
measured
validated
patient
diary
information
clinical
trial
including
eligibility
criteria
please
visit
clinical
trial
preparations
ongoing
global
registrational
trial
include
clinical
sites
within
outside
neurocrine
biosciences
voyager
therapeutics
strategic
collaboration
neurocrine
biosciences
voyager
therapeutics
entered
strategic
collaboration
focused
development
commercialization
gene
therapy
programs
parkinson
disease
friedreich
ataxia
well
rights
two
programs
determined
collaboration
combines
neurocrine
biosciences
expertise
neuroscience
drug
development
commercialization
voyager
innovative
gene
therapy
programs
targeting
severe
neurological
diseases
neurocrine
biosciences
neurocrine
biosciences
biopharmaceutical
company
years
experience
discovering
developing
treatments
people
serious
challenging
neurological
endocrine
psychiatric
disorders
company
diverse
portfolio
includes
treatments
tardive
dyskinesia
parkinson
disease
endometriosis
uterine
fibroids
three
pivotal
five
clinical
programs
multiple
therapeutic
areas
headquartered
san
diego
neurocrine
biosciences
specializes
targeting
interrupting
mechanisms
involving
interconnected
pathways
nervous
endocrine
systems
information
visit
follow
company
linkedin
collaboration
abbvie
voyager
therapeutics
voyager
therapeutics
gene
therapy
company
focused
developing
treatments
severe
neurological
diseases
voyager
committed
advancing
field
aav
gene
therapy
innovation
investment
vector
engineering
optimization
manufacturing
dosing
delivery
techniques
voyager
wholly
owned
partnered
pipeline
focuses
severe
neurological
diseases
effective
new
therapies
needed
including
parkinson
disease
huntington
disease
friedreich
ataxia
severe
neurological
diseases
information
voyager
please
visit
company
website
follow
voyagertx
twitter
linkedin
voyager
registered
trademark
voyager
therapeutics
neurocrine
biosciences
statements
addition
historical
facts
press
release
contains
statements
involve
number
risks
uncertainties
among
factors
risks
could
cause
actual
results
differ
materially
indicated
statements
risks
product
candidates
licensed
voyager
may
obtain
regulatory
approval
fda
regulatory
agencies
approval
may
delayed
conditioned
risks
development
activities
related
product
candidates
licensed
voyager
may
completed
time
risks
associated
company
dependence
voyager
research
development
manufacturing
activities
risks
ongoing
future
clinical
trials
may
successful
replicate
previous
clinical
trial
results
may
predictive
results
results
subsequent
clinical
trials
risks
uncertainties
relating
competitive
products
technological
changes
may
limit
demand
product
candidates
licensed
voyager
risks
product
candidates
licensed
voyager
may
precluded
commercialization
proprietary
rights
third
parties
impact
pandemic
efforts
mitigate
spread
business
risks
uncertainties
associated
scale
duration
pandemic
resulting
global
national
local
economic
financial
disruptions
risk
uncertainties
related
quarantines
similar
government
orders
currently
place
may
put
place
future
including
impact
orders
business
operations
business
operations
third
parties
rely
risks
related
development
product
candidates
risks
described
company
periodic
reports
filed
securities
exchange
commission
including
without
limitation
company
quarterly
report
form
quarter
ended
june
neurocrine
disclaims
obligation
update
statements
contained
press
release
date
hereof
voyager
therapeutics
statements
press
release
contains
statements
purposes
safe
harbor
provisions
private
securities
litigation
reform
act
federal
securities
laws
use
words
may
might
would
expect
plan
anticipate
believe
estimate
undoubtedly
project
intend
future
potential
continue
similar
expressions
intended
identify
statements
example
statements
voyager
therapeutics
makes
regarding
potential
impact
significance
medical
data
patients
treated
clinical
trials
phase
clinical
trial
prior
initiation
phase
clinical
trial
first
half
initiation
timing
progress
activities
goals
reporting
results
activities
associated
pd
program
potential
benefits
timing
future
operation
collaboration
neurocrine
biosciences
forward
looking
statements
based
estimates
assumptions
voyager
management
although
voyager
believes
statements
reasonable
inherently
uncertain
statements
subject
risks
uncertainties
may
cause
actual
results
differ
materially
voyager
expected
risks
uncertainties
include
among
others
risks
ongoing
future
clinical
trials
may
successful
replicate
previous
clinical
trial
results
may
predictive
results
results
subsequent
clinical
trials
risks
uncertainties
relating
competitive
products
technological
changes
may
limit
demand
product
candidates
evaluated
clinical
trials
impact
pandemic
efforts
mitigate
spread
clinical
trials
business
generally
risks
related
initiation
conduct
preclinical
studies
clinical
trials
sufficiency
preclinical
clinical
data
support
applications
additional
studies
marketing
approval
pd
drug
development
candidates
changes
expectations
fda
regulatory
authorities
requirements
obtaining
product
approvals
decisions
fda
regulatory
authorities
response
applications
file
connection
product
candidates
pd
program
otherwise
conduct
pd
drug
development
activities
priorities
capabilities
diligence
efforts
neurocrine
biosciences
collaboration
partner
pd
program
collaborators
vendors
supporting
pd
program
commercial
potential
pd
product
candidates
may
developed
part
pd
program
statements
also
subject
number
material
risks
uncertainties
described
voyager
therapeutics
annual
report
form
voyager
therapeutics
quarterly
reports
form
reports
filed
voyager
therapeutics
securities
exchange
commission
may
updated
subsequent
filings
securities
exchange
commission
information
press
release
date
press
release
statement
speaks
date
made
voyager
therapeutics
undertakes
obligation
publicly
update
revise
information
statement
whether
result
new
information
future
events
otherwise
except
required
law
contact
neurocrine
biosciences
navjot
rai
media
media
todd
tushla
investors
ir
contact
voyager
therapeutics
paul
cox
investors
pcox
sheryl
seapy
sseapy
